Segall Bryant & Hamill LLC Grows Position in CVS Health Co. (NYSE:CVS)

Segall Bryant & Hamill LLC grew its stake in CVS Health Co. (NYSE:CVS) by 4.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 30,641 shares of the pharmacy operator’s stock after buying an additional 1,269 shares during the quarter. Segall Bryant & Hamill LLC’s holdings in CVS Health were worth $1,375,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in CVS. Ridgewood Investments LLC raised its holdings in CVS Health by 255.7% during the fourth quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock valued at $28,000 after acquiring an additional 450 shares during the period. Stonebridge Financial Group LLC purchased a new position in CVS Health in the 4th quarter worth approximately $28,000. Hopwood Financial Services Inc. bought a new position in CVS Health in the 4th quarter worth approximately $29,000. Legacy Investment Solutions LLC bought a new stake in shares of CVS Health during the third quarter valued at approximately $31,000. Finally, Financial Perspectives Inc lifted its holdings in shares of CVS Health by 137.5% in the fourth quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator’s stock worth $36,000 after buying an additional 466 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Trading Down 0.7 %

Shares of NYSE CVS opened at $67.13 on Friday. The business’s 50 day moving average price is $62.12 and its 200-day moving average price is $57.67. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $79.98. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market cap of $84.64 billion, a price-to-earnings ratio of 18.34, a PEG ratio of 0.98 and a beta of 0.54.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, sell-side analysts expect that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date is Tuesday, April 22nd. CVS Health’s dividend payout ratio (DPR) is presently 72.68%.

Insider Activity at CVS Health

In other news, Director Michael F. Mahoney acquired 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was purchased at an average cost of $66.70 per share, for a total transaction of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares of the company’s stock, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the transaction, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.24% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on CVS shares. Wells Fargo & Company lifted their price target on shares of CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Truist Financial lifted their target price on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. StockNews.com upgraded CVS Health from a “sell” rating to a “hold” rating in a report on Thursday, February 13th. Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Finally, Argus set a $77.00 target price on shares of CVS Health in a report on Tuesday, February 18th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.39.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.